Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 3,591 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma, Bronchogenic Clear all
Terminated Not applicable Interventional

Yoga in Improving Quality of Life in Patients With Non-small Cell Lung Cancer Undergoing Treatment

NCT02895503
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Carcinoma
Interventions
Yoga, Support Group Therapy, FACT-L, Pulmonary function test
Behavioral · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 26, 2026, 5:48 AM EDT
Active, not recruiting Not applicable Interventional Results available

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

NCT03391362
View directory record Official record
Conditions
Brain Metastases, Small Cell Lung Cancer
Interventions
Stereotactic Radiation
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 26, 2026, 5:48 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Harvesting Cells for Experimental Cancer Treatments

NCT00068003
View directory record Official record
Conditions
Melanoma, Gastrointestinal Cancer, Metastatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer
Interventions
Anti-CD19 CAR PBL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 5:48 AM EDT
Completed No phase listed Observational

Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer

NCT03746262
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 26, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

NCT02890069
View directory record Official record
Conditions
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Interventions
PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 26, 2026, 5:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

NCT05259696
View directory record Official record
Conditions
Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
Interventions
E-602, Cemiplimab
Biological
Lead sponsor
Palleon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 26, 2026, 5:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

NCT03583086
View directory record Official record
Conditions
Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer
Interventions
Vorolanib, Nivolumab
Drug · Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Palo Alto, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 26, 2026, 5:48 AM EDT
Completed Phase 4 Interventional

Non-small Cell Lung Cancer Registry

NCT00099541
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
101
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Anaheim, California + 93 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2009 · Synced Oct 26, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional

Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer

NCT00200382
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
PS-341 (Velcade-drug)
Drug
Lead sponsor
Rasim Gucalp
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
Fitchburg, Massachusetts • Lebanon, New Hampshire • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 26, 2026, 5:48 AM EDT
Completed Phase 3 Interventional

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT02106546
View directory record Official record
Conditions
Squamous Non-Small Cell Lung Cancer
Interventions
Carboplatin, Veliparib, Paclitaxel, Placebo to veliparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
38
States / cities
Jonesboro, Arkansas • Los Angeles, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 26, 2026, 5:48 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05238883
View directory record Official record
Conditions
Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
HFB200301, Tislelizumab
Drug
Lead sponsor
HiFiBiO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 26, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

NCT01450761
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Ipilimumab, Placebo matching Ipilimumab, Etoposide, Cisplatin, Carboplatin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
42
States / cities
Hot Springs, Arkansas • Auburn, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 26, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional Results available

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

NCT02093962
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
TH-302 combination with pemetrexed, Matched placebo in combination with pemetrexed
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Chandler, Arizona • Encinitas, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 26, 2026, 5:48 AM EDT
Completed No phase listed Observational

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

NCT03546894
View directory record Official record
Conditions
Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung
Interventions
Brigatinib, Alectinib, Ceritinib, Lorlatinib, Any FDA Approved ALK Inhibitors
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Maynard, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 26, 2026, 5:48 AM EDT
Active, not recruiting Phase 1 Interventional Results available

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03132922
View directory record Official record
Conditions
Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
Interventions
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Genetic · Radiation
Lead sponsor
USWM CT, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 26, 2026, 5:48 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

NCT04471727
View directory record Official record
Conditions
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
Interventions
Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd)
Biological
Lead sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 26, 2026, 5:48 AM EDT
Completed Phase 2 Interventional

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

NCT04262856
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Interventions
Domvanalimab, Etrumadenant, Zimberelimab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Whittier, California • Englewood, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 26, 2026, 5:48 AM EDT
Recruiting Phase 2 Interventional

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
LN-145
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
27
States / cities
Gilbert, Arizona • Miami, Florida • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 26, 2026, 5:48 AM EDT
Recruiting Phase 1 Interventional

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

NCT04297605
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy)
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 26, 2026, 5:48 AM EDT
Completed No phase listed Observational

A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer

NCT03616522
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
a novel mobile phone-based intervention for automated electronic PRO collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 26, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00118131
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
13
States / cities
East Brunswick, New Jersey • Edison, New Jersey • Freehold, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 26, 2026, 5:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00750269
View directory record Official record
Conditions
Lung Cancer
Interventions
SBRT 40.0 Gy, SBRT 42.5 Gy, SBRT 45.0 Gy, SBRT 47.5 Gy, SBRT 50.0 Gy, SBRT 52.5 Gy, SBRT 55.0 Gy, SBRT 57.5 Gy, SBRT 60.0 Gy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
57
States / cities
Peoria, Arizona • Scottsdale, Arizona • Burbank, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 26, 2026, 5:48 AM EDT
Recruiting Phase 2 Interventional

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

NCT07223424
View directory record Official record
Conditions
Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular Carcinoma, Ulcerative Colitis, Esophageal Cancer, Squamous Cell Carcinoma, Gastric/GEJ, Cervical Cancer, Gastro-Esophageal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
nivolumab, pembrolizumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 26, 2026, 5:48 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

NCT00179686
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Metairie, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2006 · Synced Oct 26, 2026, 5:48 AM EDT